2018
Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI?
Ghabili K, Swallow M, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.Peer-Reviewed Original ResearchSmaller prostate volumeMulti-parametric MRISignificant prostate cancerProstate volumeProstate cancerROI ratioPSA densityGrade groupPrediction of csPCaRisk of csPCaData System (BI-RADS) category 3Prostate Imaging ReportingMpMRI findingsBiopsy databasePrior diagnosisTargeted biopsiesFusion biopsyPositive coresCsPCaUnnecessary biopsiesBiopsyMultivariate analysisPatientsImaging ReportingLesions
2017
The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men.
Syed J, Javier-desloges J, Nguyen K, Sheridan A, Levi A, Weinreb J, Sprenkle P. The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men. Journal Of Clinical Oncology 2017, 35: 29-29. DOI: 10.1200/jco.2017.35.6_suppl.29.Peer-Reviewed Original ResearchPI-RADS 4 lesionsPositive predictive valueBiopsy-naïve menNaïve menPredictive valuePI-RADS 3PI-RADS version 2PI-RADS 4Cancer detection rateChi-square testPSA densityEntire cohortMean ageFusion biopsyProstate cancerSingle lesionLesion locationGroup 2Group 1Group 3LesionsAssessment scoresLesion numberCategorical variablesFurther assessment
1998
MR-Guided Needle Aspiration Biopsies of Hepatic Masses Using a Closed Bore Magnet
Rofsky N, Yang B, Schlossberg P, Goldenberg A, Teperman L, Weinreb J. MR-Guided Needle Aspiration Biopsies of Hepatic Masses Using a Closed Bore Magnet. Journal Of Computer Assisted Tomography 1998, 22: 633-637. PMID: 9676459, DOI: 10.1097/00004728-199807000-00024.Peer-Reviewed Original ResearchConceptsNeedle aspiration biopsyHepatic massAspiration biopsyMR guidanceEfficacy of MRMetastatic carcinomaBiopsy specimensTarget lesionsNoncontrast CTHepatocellular carcinomaHepatic lesionsFocal lesionsBiopsyNecrotic materialBenign hepatocytesPatientsLesionsSmall lesionsMR-compatible needlesNondiagnostic materialPrevious CT
1995
Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast.
Petersein J, Saini S, Mitchell D, Davis P, Johnson C, Kuhlman J, Parisky Y, Runge V, Weinreb J, Bernardino M. Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast. American Journal Of Roentgenology 1995, 165: 1157-61. PMID: 7572495, DOI: 10.2214/ajr.165.5.7572495.Peer-Reviewed Original ResearchConceptsLesion-liver CNRLesion-liver contrastStandard doseHepatic lesionsMR imagingMalignant hepatic tumorsMalignant liver lesionsMalignant hepatic massesAdministration of gadoteridolMalignant hepatic lesionsT1-weighted spin-echo imagingLiver MR imagingStandard dosesHepatic massHepatic tumorsTriple doseHigh doseMalignant lesionsLiver lesionsLesionsLiver SNRDoseTime pointsGradient-echo imagingLiver signal
1994
Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions initial findings
Birnbaum B, Weinreb J, Fernandez M, Brown J, Rofsky N, Young S. Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions initial findings. Clinical Imaging 1994, 18: 21-27. PMID: 8180855, DOI: 10.1016/0899-7071(94)90141-4.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingMn-DPDPMore lesionsRetrospective multi-institutional studyExtensive metastatic diseaseHepatic magnetic resonance imagingMulti-institutional studyFocal hepatic diseaseFocal liver lesionsN'-dipyridoxylethylenediamineMetastatic diseaseIntravenous bolusDose groupFatty liverHepatic diseaseComparison of ContrastHepatic lesionsComputed tomographyLiver lesionsCT studiesPatientsMumol/Resonance imagingBolus contrastLesions
1992
Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity.
Bernardino M, Young S, Lee J, Weinreb J. Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. Radiology 1992, 183: 53-8. PMID: 1549694, DOI: 10.1148/radiology.183.1.1549694.Peer-Reviewed Original ResearchConceptsMn-DPDPMore lesionsAdditional lesionsT1-weighted imagesDose groupSerious side effectsMagnetic resonance imagingT2-weighted imagesFocal hepatic diseaseN'-dipyridoxylethylenediamineIntravenous bolusHepatic diseaseMultiinstitutional studyPatientsSide effectsLesionsResonance imagingHepatic MRManganese NImaging parametersContrast agentsImagingGroupInfusionBolus
1991
Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine.
Sze G, Brant-Zawadzki M, Haughton V, Maravilla K, McNamara M, Kumar A, Aisen A, Dreisbach J, Bradley W, Weinreb J. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 1991, 181: 693-9. PMID: 1947084, DOI: 10.1148/radiology.181.3.1947084.Peer-Reviewed Original ResearchConceptsCentral nervous systemGadodiamide injectionNervous systemMR imagingSerious adverse eventsContrast material enhancementVisualization of lesionsMagnetic resonance imagingNeurologic statusAdverse eventsMulticenter studyLaboratory valuesPatientsResonance imagingVital signsLesionsUnenhanced imagesSpinePhase IIInjectionMaterial enhancementContrast agentsMR imagesGadolinium chelate complexesImagingRenal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency.
Rofsky N, Weinreb J, Bosniak M, Libes R, Birnbaum B. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 1991, 180: 85-9. PMID: 2052729, DOI: 10.1148/radiology.180.1.2052729.Peer-Reviewed Original ResearchConceptsRenal insufficiencyGadolinium-enhanced MR imagingRenal lesionsComputed tomographyGadolinium administrationBenign cystsMR imagingSerum creatine levelsTime of nephrectomyNonenhanced Computed TomographyRenal cell carcinomaT1-weighted magnetic resonanceRenal lesion characterizationFifth patientPathologic examinationNephrotoxic reactionsUsual dosageCell carcinomaIntravenous administrationCreatine levelsMagnetic resonancePatientsIntravenous gadoliniumLesionsGadopentetate dimeglumine